Answers are grounded in this paper and cite their sources.
Discussion highlights cutaneous manifestations in T-cell malignancies post CAR T-cell therapy, indicating crucial awareness for dermatologists.
CAR T-cell therapies for blood cancers have recently been associated with secondary T-cell malignancies that can initially present on the skin. We discuss the molecular, immunological and clinical features of these cases and compare them with cutaneous and other T-cell lymphomas. Raising awareness of these secondary neoplasms is important for dermatologists who may be called on for intervention.
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: